Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...

Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...

Russian attackers were behind the hack of the European Medicines Agency EMA in 2020. They had “unauthorized access to ...

Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell ...

The European Medicines Agency said the portal will enable consultations with medical device expert panels that can promote faster access to new technologies.

The European Medicines Agency has started a review of medicines containing finasteride and dutasteride following concerns ...

Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...

C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to obtain a Drug Establishment License (DEL) to produce life-saving cell therapies ...

The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...

European Medicines Agency (EMA), in close collaboration with the European Commission, has established a standard procedure ...

C3i obtained a Drug Establishment License (DEL) to produce cell therapies for patients across Canada commercially.

MONTRÉAL — C3i Center obtains regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the European market. C3i, therefore, obtains a certificate of GMP ...